Can-Fite to Present Late-Stage Clinical Pipeline and Licensing Opportunities at BIO International Convention 2026
Can-Fite BioPharma announced it will participate in the BIO International Convention 2026 in San Diego to conduct partnering meetings for licensing and commercialization of its pipeline. The company intends to highlight its late-stage assets, including Namodenoson in pivotal Phase III for HCC and Phase IIb for MASH, and Piclidenoson in pivotal Phase III for psoriasis.
Key figures
- Patients treated safety data
- 1600
- Upfront and milestone payments to date
- $20 million
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.